The company has developed a wound treatment using white blood cells.
The wave of Israeli biomedical companies IPOs on Wall Street continues. Petah Tikva based MacroCure Ltd., which is developing cell therapy for treating severe wounds, has filed a prospectus with thhe US Securities and Exchange Commission (SEC) to raise several tens of millions of dollars on Nasdaq at a company value of $200-300 million "after money." The IPO is being led by underwriters Credit Suisse Group, Jefferies LLC, Oppenheimer & Co., and Nomura Securities International Inc.
MacroCure has developed a system for treating wounds using white blood cells from donor blood. The company said that its CureXcell product showed a 90% reduction rate in patients with deep wound infections in Israeli clinical trials.
Published by Globes [online], Israel business news - www.globes-online.com - on June 24, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2014
Nasdaq